Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HD-P023 vs Teneligliptin + Empagliflozin in Healthy Volunteers
NCT06339788Phase 1Completed
- Sponsor
- Handok
- Start
- May 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of teneligliptin + empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Handok. Primary endpoints: Area under the plasma concentration versus time curve (AUCt) at 72 hours and Peak Plasma Concentration (Cmax) at 72 hours. Started May 2024; status: completed.
02
Drugs
teneligliptin + empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06339788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06339788.